

RECIDIVE DEL DIABETE DOPO CHIRURGIA

RE-DO SURGERY?



Mirto Foletto, MD

Centro Integrato per lo Studio e la Terapia dell'Obesità'

Azienda Ospedaliera - Università' di Padova

INCONTRO CONGIUNTO

3° Workshop SICOb – SID – SIO - 7 marzo 2014

L'integrazione tra terapia medica e chirurgica nel trattamento del paziente obeso diabetico

1° Corso SICOb – SID – SIO - 8 marzo 2014

Il management peri-operatorio del paziente obeso diabetico

**Congiunto
SICOb – SIO – SID
2014**

PADOVA, 7/8 marzo

Aula Magna,
Dipartimento Militare
di Medicina Legale
Ex Ospedale Militare Padova

Con il patrocinio di



Can Diabetes Be Surgically Cured?

Long-Term Metabolic Effects of Bariatric Surgery in Obese Patients with Type 2 Diabetes Mellitus

Stacy A. Brethauer, MD, Ali Aminian, MD,* Héctor Romero-Talamás, MD,* Esam Batayyah, MD,* Jennifer Mackey, RN,* Laurence Kennedy, MD,† Sangeeta R. Kashyap, MD,† John P. Kirwan, PhD,† Tomasz Rogula, MD,* Matthew Kroh, MD,* Bipan Chand, MD,‡ and Philip R. Schauer, MD**

TABLE 1. Definitions of Glycemic Outcomes after Bariatric Surgery*

Outcome	Definition
Complete remission	Normal measures of glucose metabolism (A1C <6%, FBG <100 mg/dL) for 1 yr in the absence of antidiabetic medications.
Partial remission	Sub-diabetic hyperglycemia (A1C 6%–6.4%, FBG 100–125 mg/dL) for 1 yr in the absence of anti-diabetic medications.
Improvement	Significant reduction in A1C (by >1%) or FBG (by >25 mg/dL) OR reduction in A1C and FBG accompanied by a decrease in antidiabetic medication requirement (by discontinuing insulin or 1 oral agent, or 1/2 reduction in dose) for at least 1-yr duration.
Unchanged	The absence of remission or improvement as described earlier.
Recurrence	FBG or A1C in the diabetic range (≥ 126 mg/dL and $\geq 6.5\%$, respectively) OR need for antidiabetic medication after initial complete or partial remission.

*Criteria adapted from references 7 and 15.






TABLE 6. Long-term Bariatric Surgery Studies Reporting Biochemical Evidence of Type 2 Diabetes (T2DM) Remission

Author	Study Design	N Procedure	Follow-up Time (yr) and Rate (%)	A1C Definition of Complete Remission	Remission Rates
Adams et al ²¹	P	418 RYGB (93 T2DM) 417 nonsurgical obese control (106 T2DM) 321 population-based control (92 T2DM)	6 (93%) 6 (73%) 6 (97%)	<6.5%	62% complete 8% complete 6% complete
Sjostrom et al ³⁴	P	641 band, VBG, RYGB 627 matched controls	10 (75%) 10 (74%)	NR	36% 13%
Arterburn et al ³⁰	R	4434 RYGB	5 (68%)	<6.0%	68% complete 9% partial
Cohen et al ¹¹	P	66 RYGB	6 (100%)	<6.5%	88% complete 11% partial
Lakdawala et al ²²	P	52 RYGB	5 (100%)	<7.0%	58% complete 38% partial
Heneghan et al ³⁶	R	52 RYGB, LSG, LAGB	5 (NR)	<6.5%	44% complete 33% partial
Sultan et al ²⁸	R	95 LAGB	5 (85%)	<6.0%	40% complete 40% partial
Scopinaro et al ²³	R	312 BPD	10 (85%)	NR	97%
Pontiroli et al ²⁴	R	23 BPD 78 LAGB 37 Control	5.5 (NR)	NR	100% 66% None
Marceau et al ²⁵	R	1356 DS (377 T2DM)	7 (97%)	NR	92%
Brethauer et al (current study)	R	217 RYGB, LSG, LAGB	6 (79%)	<6.0%	24% complete 26% partial

BPD indicates biliopancreatic diversion; DS, duodenal switch; NR, not reported; P, prospective; R, retrospective; VBG, vertical banded gastroplasty.



Short- and long-term diabetes remission and recurrence rates according to procedure type.

Long-Term Effects of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Surgery on Type 2 Diabetes Mellitus in Morbidly Obese Subjects

Amanda Jiménez, MD,* Roser Casamitjana, PhD,*†‡ Lilliam Flores, MD, PhD,*†‡ Judith Viaplana, RN,‡ Ricard Corcelles, MD,* Antonio Lacy, MD, PhD,*‡ and Josep Vidal, MD, PhD*†‡





FIGURE 2. Time course of weight loss over a 5-year period in \pm standard deviation. Circle indicates RYGBP; square, SG.

Annals of Surgery • Volume 256, Number 6, December 2012

TABLE 3. Logistic Regression Analysis of Clinical Features Associated With Lack of Remission of T2DM After RYGBP or SG

	OR	95% CI	P
Use of insulin before surgery (no use as reference)	18.268	3.850–86.621	0.001
Type of surgery (RYGBP as reference)	2.031	0.606–8.362	0.320
Sex (female as reference)	2.251	0.502–8.213	0.228
Age, yr	1.026	0.955–1.103	0.483
HbA _{1c} before surgery, %	1.580	1.078–2.315	0.019
T2DM duration, yr	1.18	1.050–1.330	0.006
Body mass index before surgery, kg/m ²	0.876	0.764–1.005	0.058
Excess weight loss at the last follow-up visit, %	0.929	0.893–0.967	0.001

CI indicates confidence interval; OR, odds ratio.

TABLE 4. Cox Regression Analysis of Clinical Features Associated With Long-Term Remission and Recurrence of T2DM After RYGBP or SG

	Long-Term Remission			Recurrence		
	HR	95% CI	P	HR	95% CI	P
Type of surgery (SG = 1/RYGBP = 0)	1.901	1.078–3.351	0.026	3.566	0.507–25.072	0.201
Sex(female = 1/male = 0)	0.835	0.525–1.328	0.446	0.850	0.112–6.485	0.876
Age, yr	0.975	0.952–0.999	0.041	1.100	1.000–1.209	0.05
Body mass index before surgery,kg/m ²	0.969	0.931–1.007	0.112	0.966	0.800–1.166	0.717
HbA _{1c} before surgery, %	0.870	0.759–0.997	0.044	0.916	0.589–1.609	0.916
T2DM duration, yr	0.972	0.912–1.037	0.387	0.837	0.631–1.111	0.218
Use of insulin before surgery (use = 1/not use = 0)	0.389	0.157–0.961	0.041	204.997	1.843–1655.137	0.005
Excess weight loss at last follow-up,%	1.024	1.014–1.035	<0.001	0.953	0.884–1.028	0.216
Weight regain after remission (yes = 1/no = 0)	—	—	—	55.236	5.321–2383.678	0.021


CI indicates confidence interval; HR, hazard ratio.





A Multisite Study of Long-term Remission and Relapse of Type 2 Diabetes Mellitus Following Gastric Bypass

David E. Arterburn · Andy Bogart · Nancy E. Sherwood ·
Stephen Sidney · Karen J. Coleman · Sebastien Haneel
Patrick J. O'Connor · Mary Kay Theis · Guilherme M
David McCulloch · Joe Selby







Fig. 4 Body mass index trajectories for gastric bypass patients who never completely remit diabetes, durably remit diabetes, and remit but subsequently relapse diabetes. The *left-hand figure* presents the unadjusted lowess smoothed BMI trajectories for each group, and the *right-*



hand figure presents the multivariable adjusted and intensity-weighted plots for each group. Legend for the above plots: solid line = never remitted; dash-dot = remitted and relapsed; dotted line = durable remission

METABOLIC SURGERY, WEIGHT REGAIN AND DIABETES RE-EMERGENCE

Cirurgia metabólica, reganho de peso e recidiva do diabetes

Josemberg M. CAMPOS¹, Daniel C. LINS^{1,2}, Lyz B. SILVA¹,
José Guido C. ARAUJO-JUNIOR¹, Jorge L. M. ZEVE¹, Álvaro A. B. FERRAZ¹


Author	n	Surgery	Follow-up	Pre-op BMI (mean ± SD)	Initial diabetes remission(%)	Weight regain (%)	Recurrence of diabetes after follow-up (%)	Adequate glycemic control after follow-up (%)
DiGiorgi	42	RYGB	≥ 3 years	51,4 ± 8,7	64%	21% of lost weight was regained	26%	-
Chikunguwo	177		5 – 16 years	50,2 ± 8,1	88,7%	-	43,3%	-
	15			51,2 ± 6,4		100%	-	80%
Araujo	35 (control)		64,8 months	42,8 ± 5,4		0%	-	86,7%

Variable	Evaluation time and differences	Group	
		Weight regain (n=15) (mean ± SD)	Control (n=30) (mean ± SD)
Age		45,47 ± 12,34	44,77 ± 11,80
BMI (kg/m ²)	Pre	51,18 ± 6,39	42,86 ± 5,36
	Post 1	32,52 ± 1,62	25,30 ± 2,49
	Post 2	39,33 ± 5,49	26,90 ± 2,20
Follow-up	Post 1	17,60 ± 5,77	21,10 ± 10,99
	Post 2	64,80 ± 22,59	48,80 ± 13,35
		n (%)	n (%)
Controlled HbA1c	Post 2	12 (80.0)	26 (86.7)
	Pre	4 (26.7)	10 (33.3)
Controlled glycemia	Post 1	13 (86.7)	28 (93.3)
	Post 2	13 (86.7)	26 (86.7)
Complete remission of T2DM	Post 2	11 (73.3)	24 (80.0)
Complete + Partial Remission of T2DM	Post 2	11 (73.3)	25 (83.3)

T2DM=type 2 diabetes mellitus. Pre = Preoperative. Post = Postoperative

T2DM Rec Rs w/wo weight regain are similar (FU 65 mos)

Key issue: correct timing of T2DM dx



Update: Why Diabetes Does Not Resolve in Some Patients after Bariatric Surgery

Mervyn Deitel

Table 1 Why diabetes does not resolve after bariatric surgery in some patients

Inadequate weight loss
Over-indulgence in high-caloric foods
Lack of compliance with diet and exercise
Longstanding poorly controlled or aggressive type 2 diabetes
Lower preoperative BMI
Surgical technique—pouch and/or stoma constructed too large, resulting in inadequate gastric restriction
Diabetes actually a type 1 (LADA)

Table 2 Latent autoimmune diabetes in the adult (LADA): a type 1

Onset ages 30–55 years
Slow autoimmune destruction of beta cells
9–25% of adult diabetic population
Low or absent plasma insulin
Very low fasting and meal-stimulated C-peptide
Antibodies to GAD, insulin and/or islet cells
Possible history of other autoimmune disease
May respond to oral anti-diabetes medications while 20% of beta cells are still functioning
Progresses to requiring insulin

GAD glutamic acid decarboxylate

after multidisciplinary reassessment





possible surgical targets

- Inadequate weight loss

CONVERSION

switch operation



- Poor surgical technique

REVISION

pouch and stoma



grazie per l'attenzione!

Andrea
Pazienza